VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy 2021 | CITE-seq analysis predicts response to CAR-T therapy and bispecifics in myeloma

Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) is a single cell sequencing method that enables detailed immunophenotypic profiling and transcriptomic analysis of cells on a single cell level. Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, talks on the use of CITE-seq in multiple myeloma patients undergoing CAR-T or bispecific antibody therapy. Analyzing the immunophenotypic profile of a patient’s T-cells prior to treatment can predict if they are likely to respond to the therapy. T-cells in the bone marrow and peripheral blood of sensitive patients are more central memory-like, whereas an exhausted T-cell phenotype if often seen in those resistant to CAR-T therapy and bispecifics. Transcriptomic data analysis is also beneficial to improve our understanding of the drivers of T-cell phenotypes. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.

Disclosures

Speaker bureau/honoraria: BMS, Janssen
Consulting fees: BMS, Janssen

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter